Gut Microbiome and Response to Cardiovascular Drugs
Gut Microbiome and Response to Cardiovascular Drugs
复制标题
DOI：
10.1161/circgen.119.002314
复制
发表时间：
2019-09-01
影响因子：
7.4
通讯作者：
Ferguson, Jane F.
中科院分区：
文献类型：
--
作者：
Tuteja, Sony;Ferguson, Jane F.
肠道微生物组正在成为心血管疾病风险和外源性物质代谢的重要贡献者。肠道微生物群的改变与动脉粥样硬化、血脂异常、高血压和心力衰竭有关。微生物群具有代谢药物的能力，这可能导致药物药代动力学和药效学改变或形成毒性代谢物，从而干扰药物反应。早期证据表明，肠道微生物组调节对他汀类药物和抗高血压药物的反应。在这篇综述中，我们将重点介绍肠道微生物组促进药物生物转化和影响药理学疗效的机制。更好地了解肠道微生物组，宿主因素和对药物的反应的复杂相互作用对于开发针对CVD的新型精确疗法至关重要。
The gut microbiome is emerging as an important contributor to both cardiovascular disease risk and metabolism of xenobiotics. Alterations in the intestinal microbiota are associated with atherosclerosis, dyslipidemia, hypertension, and heart failure. The microbiota have the ability to metabolize medications, which can results in altered drug pharmacokinetics and pharmacodynamics or formation of toxic metabolites which can interfere with drug response. Early evidence suggests that the gut microbiome modulates response to statins and antihypertensive medications. In this review, we will highlight mechanisms by which the gut microbiome facilitates the biotransformation of drugs and impacts pharmacological efficacy. A better understanding of the complex interactions of the gut microbiome, host factors, and response to medications will be important for the development of novel precision therapeutics for targeting CVD.